Pharmacokinetics(PK) study of meropenem in Epithelial Lining Fluid (ELF), an open-label study
Not Applicable
- Conditions
- Healthy volunteer
- Registration Number
- JPRN-UMIN000010941
- Lead Sponsor
- Keio University, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of hypersensitivity caused by lidocaine hydrochloride. 2) History of hypersensitivity caused by carbapenem. 3) In medication. 4) Creatinine clearance <=30mL/min. 5) Smorker. 6) Hepatic or Renal disorder, Anemia proved by the pre-medical test. 7)Any other participants whose condition is inappropriate for the evaluation of this clinical study, judged by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate PK in plasma and ELF of meropenem, the ratio ELF:plasma of meropenem
- Secondary Outcome Measures
Name Time Method To evaluate inflammatory cytokines (IL-1, IL-2, IL-6, IL-10, pro-calcitonine, etc) in serum after BMS.